{"data":[{"accessionNo":"0001104659-26-097205","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001842295","issuerName":"Maze Therapeutics, Inc.","ticker":"MAZE","cusip":"578784100","securityClass":"Common Stock, $0.001 par value per share","eventDate":"2026-06-30","reportingPerson":"Paradigm BioCapital Advisors GP LLC","reportingCik":null,"personType":"OO","sharesOwned":0,"percentOfClass":0,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/maze"},{"accessionNo":"0001104659-26-097205","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001842295","issuerName":"Maze Therapeutics, Inc.","ticker":"MAZE","cusip":"578784100","securityClass":"Common Stock, $0.001 par value per share","eventDate":"2026-06-30","reportingPerson":"Paradigm BioCapital Advisors LP","reportingCik":null,"personType":"PN","sharesOwned":0,"percentOfClass":0,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/maze"},{"accessionNo":"0001104659-26-097205","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001842295","issuerName":"Maze Therapeutics, Inc.","ticker":"MAZE","cusip":"578784100","securityClass":"Common Stock, $0.001 par value per share","eventDate":"2026-06-30","reportingPerson":"Senai Asefaw, M.D.","reportingCik":null,"personType":"IN","sharesOwned":0,"percentOfClass":0,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/maze"},{"accessionNo":"0001104659-26-097205","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001842295","issuerName":"Maze Therapeutics, Inc.","ticker":"MAZE","cusip":"578784100","securityClass":"Common Stock, $0.001 par value per share","eventDate":"2026-06-30","reportingPerson":"Paradigm BioCapital International Fund Ltd.","reportingCik":null,"personType":"CO","sharesOwned":0,"percentOfClass":0,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/maze"},{"accessionNo":"0002012383-26-002905","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001842295","issuerName":"MAZE THERAPEUTICS INC","ticker":"MAZE","cusip":"578784100","securityClass":"Common Stock","eventDate":"2026-06-30","reportingPerson":"BlackRock, Inc.","reportingCik":null,"personType":"HC","sharesOwned":2978114,"percentOfClass":5.4,"filedAt":"2026-07-29","canonicalUrl":"https://xoomar.com/markets/stocks/maze"},{"accessionNo":"0001274173-26-000143","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0001842295","issuerName":"MAZE THERAPEUTICS, INC.","ticker":"MAZE","cusip":"578784100","securityClass":"Common Stock","eventDate":"2026-03-31","reportingPerson":"JANUS HENDERSON GROUP PLC","reportingCik":null,"personType":"HC","sharesOwned":2858876,"percentOfClass":5.8,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/maze"},{"accessionNo":"0001104659-26-038490","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001842295","issuerName":"Maze Therapeutics, Inc.","ticker":"MAZE","cusip":"578784100","securityClass":"Common Stock, $0.001 par value per share","eventDate":"2026-03-25","reportingPerson":"Senai Asefaw, M.D.","reportingCik":null,"personType":"IN","sharesOwned":3051087,"percentOfClass":6.1,"filedAt":"2026-04-01","canonicalUrl":"https://xoomar.com/markets/stocks/maze"},{"accessionNo":"0001104659-26-038490","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001842295","issuerName":"Maze Therapeutics, Inc.","ticker":"MAZE","cusip":"578784100","securityClass":"Common Stock, $0.001 par value per share","eventDate":"2026-03-25","reportingPerson":"Paradigm BioCapital Advisors LP","reportingCik":null,"personType":"PN","sharesOwned":3051087,"percentOfClass":6.1,"filedAt":"2026-04-01","canonicalUrl":"https://xoomar.com/markets/stocks/maze"},{"accessionNo":"0001104659-26-038490","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001842295","issuerName":"Maze Therapeutics, Inc.","ticker":"MAZE","cusip":"578784100","securityClass":"Common Stock, $0.001 par value per share","eventDate":"2026-03-25","reportingPerson":"Paradigm BioCapital Advisors GP LLC","reportingCik":null,"personType":"OO","sharesOwned":3051087,"percentOfClass":6.1,"filedAt":"2026-04-01","canonicalUrl":"https://xoomar.com/markets/stocks/maze"},{"accessionNo":"0001104659-26-038490","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001842295","issuerName":"Maze Therapeutics, Inc.","ticker":"MAZE","cusip":"578784100","securityClass":"Common Stock, $0.001 par value per share","eventDate":"2026-03-25","reportingPerson":"Paradigm BioCapital International Fund Ltd.","reportingCik":null,"personType":"CO","sharesOwned":2688520,"percentOfClass":5.4,"filedAt":"2026-04-01","canonicalUrl":"https://xoomar.com/markets/stocks/maze"},{"accessionNo":"0001193125-26-051800","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001842295","issuerName":"Maze Therapeutics, Inc.","ticker":"MAZE","cusip":null,"securityClass":"Common Stock, $0.001 par value per share","eventDate":"2025-12-31","reportingPerson":"TRV GP IV, LLC","reportingCik":null,"personType":"OO","sharesOwned":4473958,"percentOfClass":9.3,"filedAt":"2026-02-13","canonicalUrl":"https://xoomar.com/markets/stocks/maze"},{"accessionNo":"0001193125-26-051800","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001842295","issuerName":"Maze Therapeutics, Inc.","ticker":"MAZE","cusip":null,"securityClass":"Common Stock, $0.001 par value per share","eventDate":"2025-12-31","reportingPerson":"Third Rock Ventures GP IV, L.P.","reportingCik":null,"personType":"PN","sharesOwned":4473958,"percentOfClass":9.3,"filedAt":"2026-02-13","canonicalUrl":"https://xoomar.com/markets/stocks/maze"},{"accessionNo":"0001193125-26-051800","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001842295","issuerName":"Maze Therapeutics, Inc.","ticker":"MAZE","cusip":null,"securityClass":"Common Stock, $0.001 par value per share","eventDate":"2025-12-31","reportingPerson":"Third Rock Ventures IV, L.P.","reportingCik":null,"personType":"PN","sharesOwned":4473958,"percentOfClass":9.3,"filedAt":"2026-02-13","canonicalUrl":"https://xoomar.com/markets/stocks/maze"},{"accessionNo":"0001231919-26-000147","formType":"SCHEDULE 13G/A","amendmentNo":4,"issuerCik":"0001842295","issuerName":"Maze Therapeutics, Inc.","ticker":"MAZE","cusip":null,"securityClass":"Common Stock - par value $0.001 per share","eventDate":"2025-12-31","reportingPerson":"FHMLSP, L.L.C.","reportingCik":null,"personType":"OO","sharesOwned":4342266,"percentOfClass":9,"filedAt":"2026-02-13","canonicalUrl":"https://xoomar.com/markets/stocks/maze"},{"accessionNo":"0001231919-26-000147","formType":"SCHEDULE 13G/A","amendmentNo":4,"issuerCik":"0001842295","issuerName":"Maze Therapeutics, Inc.","ticker":"MAZE","cusip":null,"securityClass":"Common Stock - par value $0.001 per share","eventDate":"2025-12-31","reportingPerson":"Frazier Life Sciences Public Fund, L.P.","reportingCik":null,"personType":"PN","sharesOwned":4342266,"percentOfClass":9,"filedAt":"2026-02-13","canonicalUrl":"https://xoomar.com/markets/stocks/maze"},{"accessionNo":"0001231919-26-000147","formType":"SCHEDULE 13G/A","amendmentNo":4,"issuerCik":"0001842295","issuerName":"Maze Therapeutics, Inc.","ticker":"MAZE","cusip":null,"securityClass":"Common Stock - par value $0.001 per share","eventDate":"2025-12-31","reportingPerson":"FHMLSP, L.P.","reportingCik":null,"personType":"PN","sharesOwned":4342266,"percentOfClass":9,"filedAt":"2026-02-13","canonicalUrl":"https://xoomar.com/markets/stocks/maze"},{"accessionNo":"0001193125-26-051800","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001842295","issuerName":"Maze Therapeutics, Inc.","ticker":"MAZE","cusip":null,"securityClass":"Common Stock, $0.001 par value per share","eventDate":"2025-12-31","reportingPerson":"Third Rock Ventures V, L.P.","reportingCik":null,"personType":"PN","sharesOwned":950800,"percentOfClass":2,"filedAt":"2026-02-13","canonicalUrl":"https://xoomar.com/markets/stocks/maze"},{"accessionNo":"0001193125-26-051800","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001842295","issuerName":"Maze Therapeutics, Inc.","ticker":"MAZE","cusip":null,"securityClass":"Common Stock, $0.001 par value per share","eventDate":"2025-12-31","reportingPerson":"Third Rock Ventures GP V, L.P.","reportingCik":null,"personType":"PN","sharesOwned":950800,"percentOfClass":2,"filedAt":"2026-02-13","canonicalUrl":"https://xoomar.com/markets/stocks/maze"},{"accessionNo":"0001193125-26-051800","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001842295","issuerName":"Maze Therapeutics, Inc.","ticker":"MAZE","cusip":null,"securityClass":"Common Stock, $0.001 par value per share","eventDate":"2025-12-31","reportingPerson":"TRV GP V, LLC","reportingCik":null,"personType":"OO","sharesOwned":950800,"percentOfClass":2,"filedAt":"2026-02-13","canonicalUrl":"https://xoomar.com/markets/stocks/maze"},{"accessionNo":"0001231919-26-000147","formType":"SCHEDULE 13G/A","amendmentNo":4,"issuerCik":"0001842295","issuerName":"Maze Therapeutics, Inc.","ticker":"MAZE","cusip":null,"securityClass":"Common Stock - par value $0.001 per share","eventDate":"2025-12-31","reportingPerson":"FHMLS XI, L.L.C.","reportingCik":null,"personType":"OO","sharesOwned":149026,"percentOfClass":0.3,"filedAt":"2026-02-13","canonicalUrl":"https://xoomar.com/markets/stocks/maze"},{"accessionNo":"0001231919-26-000147","formType":"SCHEDULE 13G/A","amendmentNo":4,"issuerCik":"0001842295","issuerName":"Maze Therapeutics, Inc.","ticker":"MAZE","cusip":null,"securityClass":"Common Stock - par value $0.001 per share","eventDate":"2025-12-31","reportingPerson":"FHMLS XI, L.P.","reportingCik":null,"personType":"PN","sharesOwned":149026,"percentOfClass":0.3,"filedAt":"2026-02-13","canonicalUrl":"https://xoomar.com/markets/stocks/maze"},{"accessionNo":"0001231919-26-000147","formType":"SCHEDULE 13G/A","amendmentNo":4,"issuerCik":"0001842295","issuerName":"Maze Therapeutics, Inc.","ticker":"MAZE","cusip":null,"securityClass":"Common Stock - par value $0.001 per share","eventDate":"2025-12-31","reportingPerson":"Frazier Life Sciences XI, L.P.","reportingCik":null,"personType":"PN","sharesOwned":149026,"percentOfClass":0.3,"filedAt":"2026-02-13","canonicalUrl":"https://xoomar.com/markets/stocks/maze"},{"accessionNo":"0001231919-26-000147","formType":"SCHEDULE 13G/A","amendmentNo":4,"issuerCik":"0001842295","issuerName":"Maze Therapeutics, Inc.","ticker":"MAZE","cusip":null,"securityClass":"Common Stock - par value $0.001 per share","eventDate":"2025-12-31","reportingPerson":"James N. Topper","reportingCik":null,"personType":"IN","sharesOwned":75982,"percentOfClass":0.2,"filedAt":"2026-02-13","canonicalUrl":"https://xoomar.com/markets/stocks/maze"},{"accessionNo":"0001231919-26-000147","formType":"SCHEDULE 13G/A","amendmentNo":4,"issuerCik":"0001842295","issuerName":"Maze Therapeutics, Inc.","ticker":"MAZE","cusip":null,"securityClass":"Common Stock - par value $0.001 per share","eventDate":"2025-12-31","reportingPerson":"Patrick J. Heron","reportingCik":null,"personType":"IN","sharesOwned":75982,"percentOfClass":0.2,"filedAt":"2026-02-13","canonicalUrl":"https://xoomar.com/markets/stocks/maze"},{"accessionNo":"0001231919-26-000147","formType":"SCHEDULE 13G/A","amendmentNo":4,"issuerCik":"0001842295","issuerName":"Maze Therapeutics, Inc.","ticker":"MAZE","cusip":null,"securityClass":"Common Stock - par value $0.001 per share","eventDate":"2025-12-31","reportingPerson":"FHMLS X, L.L.C.","reportingCik":null,"personType":"OO","sharesOwned":75982,"percentOfClass":0.2,"filedAt":"2026-02-13","canonicalUrl":"https://xoomar.com/markets/stocks/maze"},{"accessionNo":"0001231919-26-000147","formType":"SCHEDULE 13G/A","amendmentNo":4,"issuerCik":"0001842295","issuerName":"Maze Therapeutics, Inc.","ticker":"MAZE","cusip":null,"securityClass":"Common Stock - par value $0.001 per share","eventDate":"2025-12-31","reportingPerson":"FHMLS X, L.P.","reportingCik":null,"personType":"PN","sharesOwned":75982,"percentOfClass":0.2,"filedAt":"2026-02-13","canonicalUrl":"https://xoomar.com/markets/stocks/maze"},{"accessionNo":"0001231919-26-000147","formType":"SCHEDULE 13G/A","amendmentNo":4,"issuerCik":"0001842295","issuerName":"Maze Therapeutics, Inc.","ticker":"MAZE","cusip":null,"securityClass":"Common Stock - par value $0.001 per share","eventDate":"2025-12-31","reportingPerson":"Frazier Life Sciences X, L.P.","reportingCik":null,"personType":"PN","sharesOwned":75982,"percentOfClass":0.2,"filedAt":"2026-02-13","canonicalUrl":"https://xoomar.com/markets/stocks/maze"},{"accessionNo":"0001231919-26-000147","formType":"SCHEDULE 13G/A","amendmentNo":4,"issuerCik":"0001842295","issuerName":"Maze Therapeutics, Inc.","ticker":"MAZE","cusip":null,"securityClass":"Common Stock - par value $0.001 per share","eventDate":"2025-12-31","reportingPerson":"Frazier Life Sciences XII, L.P.","reportingCik":null,"personType":"PN","sharesOwned":0,"percentOfClass":0,"filedAt":"2026-02-13","canonicalUrl":"https://xoomar.com/markets/stocks/maze"},{"accessionNo":"0001231919-26-000147","formType":"SCHEDULE 13G/A","amendmentNo":4,"issuerCik":"0001842295","issuerName":"Maze Therapeutics, Inc.","ticker":"MAZE","cusip":null,"securityClass":"Common Stock - par value $0.001 per share","eventDate":"2025-12-31","reportingPerson":"FHMLS XII, L.P.","reportingCik":null,"personType":"PN","sharesOwned":0,"percentOfClass":0,"filedAt":"2026-02-13","canonicalUrl":"https://xoomar.com/markets/stocks/maze"},{"accessionNo":"0001231919-26-000147","formType":"SCHEDULE 13G/A","amendmentNo":4,"issuerCik":"0001842295","issuerName":"Maze Therapeutics, Inc.","ticker":"MAZE","cusip":null,"securityClass":"Common Stock - par value $0.001 per share","eventDate":"2025-12-31","reportingPerson":"FHMLS XII, L.L.C.","reportingCik":null,"personType":"OO","sharesOwned":0,"percentOfClass":0,"filedAt":"2026-02-13","canonicalUrl":"https://xoomar.com/markets/stocks/maze"},{"accessionNo":"0001168404-26-000010","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001842295","issuerName":"MAZE THERAPEUTICS, INC.","ticker":"MAZE","cusip":null,"securityClass":"Common Stock, par value $0.001 per share","eventDate":"2025-12-31","reportingPerson":"Alphabet Inc.","reportingCik":null,"personType":"HC,CO","sharesOwned":1388583,"percentOfClass":2.9,"filedAt":"2026-02-06","canonicalUrl":"https://xoomar.com/markets/stocks/maze"},{"accessionNo":"0001168404-26-000010","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001842295","issuerName":"MAZE THERAPEUTICS, INC.","ticker":"MAZE","cusip":null,"securityClass":"Common Stock, par value $0.001 per share","eventDate":"2025-12-31","reportingPerson":"XXVI Holdings Inc.","reportingCik":null,"personType":"CO","sharesOwned":1388583,"percentOfClass":2.9,"filedAt":"2026-02-06","canonicalUrl":"https://xoomar.com/markets/stocks/maze"},{"accessionNo":"0001168404-26-000010","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001842295","issuerName":"MAZE THERAPEUTICS, INC.","ticker":"MAZE","cusip":null,"securityClass":"Common Stock, par value $0.001 per share","eventDate":"2025-12-31","reportingPerson":"Alphabet Holdings LLC","reportingCik":null,"personType":"OO","sharesOwned":1388583,"percentOfClass":2.9,"filedAt":"2026-02-06","canonicalUrl":"https://xoomar.com/markets/stocks/maze"},{"accessionNo":"0001168404-26-000010","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001842295","issuerName":"MAZE THERAPEUTICS, INC.","ticker":"MAZE","cusip":null,"securityClass":"Common Stock, par value $0.001 per share","eventDate":"2025-12-31","reportingPerson":"GV 2019, L.P.","reportingCik":null,"personType":"PN","sharesOwned":784019,"percentOfClass":1.6,"filedAt":"2026-02-06","canonicalUrl":"https://xoomar.com/markets/stocks/maze"},{"accessionNo":"0001168404-26-000010","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001842295","issuerName":"MAZE THERAPEUTICS, INC.","ticker":"MAZE","cusip":null,"securityClass":"Common Stock, par value $0.001 per share","eventDate":"2025-12-31","reportingPerson":"GV 2019 GP, L.P.","reportingCik":null,"personType":"PN","sharesOwned":784019,"percentOfClass":1.6,"filedAt":"2026-02-06","canonicalUrl":"https://xoomar.com/markets/stocks/maze"},{"accessionNo":"0001168404-26-000010","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001842295","issuerName":"MAZE THERAPEUTICS, INC.","ticker":"MAZE","cusip":null,"securityClass":"Common Stock, par value $0.001 per share","eventDate":"2025-12-31","reportingPerson":"GV 2019 GP, L.L.C.","reportingCik":null,"personType":"OO","sharesOwned":784019,"percentOfClass":1.6,"filedAt":"2026-02-06","canonicalUrl":"https://xoomar.com/markets/stocks/maze"},{"accessionNo":"0001168404-26-000010","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001842295","issuerName":"MAZE THERAPEUTICS, INC.","ticker":"MAZE","cusip":null,"securityClass":"Common Stock, par value $0.001 per share","eventDate":"2025-12-31","reportingPerson":"GV 2023 GP, L.L.C.","reportingCik":null,"personType":"OO","sharesOwned":604564,"percentOfClass":1.3,"filedAt":"2026-02-06","canonicalUrl":"https://xoomar.com/markets/stocks/maze"},{"accessionNo":"0001168404-26-000010","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001842295","issuerName":"MAZE THERAPEUTICS, INC.","ticker":"MAZE","cusip":null,"securityClass":"Common Stock, par value $0.001 per share","eventDate":"2025-12-31","reportingPerson":"GV 2023 GP, L.P.","reportingCik":null,"personType":"PN","sharesOwned":604564,"percentOfClass":1.3,"filedAt":"2026-02-06","canonicalUrl":"https://xoomar.com/markets/stocks/maze"},{"accessionNo":"0001168404-26-000010","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001842295","issuerName":"MAZE THERAPEUTICS, INC.","ticker":"MAZE","cusip":null,"securityClass":"Common Stock, par value $0.001 per share","eventDate":"2025-12-31","reportingPerson":"GV 2023, L.P.","reportingCik":null,"personType":"PN","sharesOwned":604564,"percentOfClass":1.3,"filedAt":"2026-02-06","canonicalUrl":"https://xoomar.com/markets/stocks/maze"},{"accessionNo":"0001274173-25-000316","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001842295","issuerName":"MAZE THERAPEUTICS, INC.","ticker":"MAZE","cusip":null,"securityClass":"Common Stock","eventDate":"2025-09-30","reportingPerson":"JANUS HENDERSON GROUP PLC","reportingCik":null,"personType":"IA,HC","sharesOwned":3206472,"percentOfClass":7.3,"filedAt":"2025-11-14","canonicalUrl":"https://xoomar.com/markets/stocks/maze"},{"accessionNo":"0001104659-25-112467","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001842295","issuerName":"Maze Therapeutics, Inc.","ticker":"MAZE","cusip":null,"securityClass":"Common Stock, par value $0.001","eventDate":"2025-09-30","reportingPerson":"James Tananbaum","reportingCik":null,"personType":"IN","sharesOwned":608948,"percentOfClass":1.4,"filedAt":"2025-11-14","canonicalUrl":"https://xoomar.com/markets/stocks/maze"},{"accessionNo":"0001104659-25-112467","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001842295","issuerName":"Maze Therapeutics, Inc.","ticker":"MAZE","cusip":null,"securityClass":"Common Stock, par value $0.001","eventDate":"2025-09-30","reportingPerson":"Foresite Capital Fund IV, L.P.","reportingCik":null,"personType":"PN","sharesOwned":522657,"percentOfClass":1.2,"filedAt":"2025-11-14","canonicalUrl":"https://xoomar.com/markets/stocks/maze"},{"accessionNo":"0001104659-25-112467","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001842295","issuerName":"Maze Therapeutics, Inc.","ticker":"MAZE","cusip":null,"securityClass":"Common Stock, par value $0.001","eventDate":"2025-09-30","reportingPerson":"Foresite Capital Management IV, LLC","reportingCik":null,"personType":"OO","sharesOwned":522657,"percentOfClass":1.2,"filedAt":"2025-11-14","canonicalUrl":"https://xoomar.com/markets/stocks/maze"},{"accessionNo":"0001104659-25-112467","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001842295","issuerName":"Maze Therapeutics, Inc.","ticker":"MAZE","cusip":null,"securityClass":"Common Stock, par value $0.001","eventDate":"2025-09-30","reportingPerson":"Foresite Capital Management V, LLC","reportingCik":null,"personType":"OO","sharesOwned":86291,"percentOfClass":0.2,"filedAt":"2025-11-14","canonicalUrl":"https://xoomar.com/markets/stocks/maze"},{"accessionNo":"0001104659-25-112467","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001842295","issuerName":"Maze Therapeutics, Inc.","ticker":"MAZE","cusip":null,"securityClass":"Common Stock, par value $0.001","eventDate":"2025-09-30","reportingPerson":"Foresite Capital Fund V, L.P.","reportingCik":null,"personType":"PN","sharesOwned":86291,"percentOfClass":0.2,"filedAt":"2025-11-14","canonicalUrl":"https://xoomar.com/markets/stocks/maze"},{"accessionNo":"0000902664-25-004912","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001842295","issuerName":"Maze Therapeutics, Inc.","ticker":"MAZE","cusip":null,"securityClass":"Common Stock, par value $0.001 per share","eventDate":"2025-09-30","reportingPerson":"Matrix Capital Management Company, LP","reportingCik":null,"personType":"IA,PN","sharesOwned":1653684,"percentOfClass":3.5,"filedAt":"2025-11-13","canonicalUrl":"https://xoomar.com/markets/stocks/maze"},{"accessionNo":"0000902664-25-004912","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001842295","issuerName":"Maze Therapeutics, Inc.","ticker":"MAZE","cusip":null,"securityClass":"Common Stock, par value $0.001 per share","eventDate":"2025-09-30","reportingPerson":"DAVID E. GOEL","reportingCik":null,"personType":"HC,IN","sharesOwned":1653684,"percentOfClass":3.5,"filedAt":"2025-11-13","canonicalUrl":"https://xoomar.com/markets/stocks/maze"}],"updatedAt":"2026-11-04T03:31:31.728Z","source":"xoomar.com","docs":"https://xoomar.com/markets/api","license":"https://xoomar.com/terms","attribution":"Credit XOOMAR with a link to the dataset page on xoomar.com when you republish this data","canonicalUrl":"https://xoomar.com/markets/stocks/maze","meta":{"source":"SEC","sourceAttribution":"Schedule 13D and 13G data: SEC.","notice":"10 requests a minute without a key, 30 with a free key. Get a free key at https://xoomar.com/signup?utm_source=api, register your app at https://xoomar.com/developers/register?utm_source=api, and credit the data as \"Data: XOOMAR\" together with the sourceAttribution line."}}